| Literature DB >> 28072838 |
Robin W M Vernooij1, Pablo Alonso-Coello1,2,3, Melissa Brouwers4, Laura Martínez García1.
Abstract
BACKGROUND: Scientific knowledge is in constant development. Consequently, regular review to assure the trustworthiness of clinical guidelines is required. However, there is still a lack of preferred reporting items of the updating process in updated clinical guidelines. The present article describes the development process of the Checklist for the Reporting of Updated Guidelines (CheckUp). METHODS ANDEntities:
Mesh:
Year: 2017 PMID: 28072838 PMCID: PMC5224740 DOI: 10.1371/journal.pmed.1002207
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Checklist development process.
Abbreviation: AGREE, Appraisal of Guidelines for Research and Evaluation.
CheckUp: Stages of the optimisation process (objective, sample, and results by optimisation processes).
| Stage | Objectives | Sample ( | Main Results |
|---|---|---|---|
Assess whether the terminology was consistent between the checklist and updated clinical guidelines Identify items that were lacking in the checklist. | Updated clinical guidelines (10). | No items were modified. No new items were added. | |
Explore challenges and issues regarding the clinical guideline updating process. Identify items that were lacking in the checklist. | Clinical guideline updating process experts (13). | Five items had major modifications. Four new items were added. | |
Assess the inclusion, comprehensiveness, clarity, and coverage of each item. Identify items that were lacking in the checklist. | Clinical guideline updating process experts (33) (CheckUp panel). | All items, explanations, and examples had minor modifications regarding writing style. Two items were combined. No new items were added. | |
Evaluate the usability of the checklist. | Clinical guideline methodologists (53). | All items, explanations, and examples had minor modifications regarding writing style. | |
Clinical guideline users (10). | No items were modified. |
Results of the Delphi survey (third round).
| Item | Median Score for Inclusion | Median Score for Completeness | Median Score for Usability | Median Score for Quality |
|---|---|---|---|---|
| 1. Distinguishing the updated and original version. | 7 | 6 | 6 | 6 |
| 2. Reviewed and changed sections. | 6 | 6 | 6 | 5 |
| 3. Presentation of new, modified, or not changed recommendations. | 7 | 6 | 6 | 6 |
| 4. Working group of the updating process. | 6 | 6 | 5 | 6 |
| 5. Rationale for updating the guideline. | 6 | 6 | 5 | 6 |
| 6. Differences in the scope and purpose between the updated and the original guideline. | 6 | 6 | 6 | 5.5 |
| 7. Reporting and justification of changes in the recommendations. | 6 | 6.5 | 6 | 6 |
| 8. Methods for searching and identifying new evidence. | 7 | 7 | 6 | 7 |
| 9. Methods for evidence selection. | 6.5 | 7 | 6 | 7 |
| 10. Methods to assess the quality of the included evidence. | 7 | 6 | 6 | 6 |
| 11. Methods for evidence synthesis. | 6 | 6 | 6 | 6 |
| 12. Methods and plan for implementing the changes. | 6 | 6 | 6 | 6 |
| 13. Methods for external reviewing. | 6 | 6 | 5.5 | 6 |
| 14. Plan and methods for updating in the future. | 6 | 6 | 5 | 6 |
| 15. Conflicts of interests of the updating group. | 7 | 7 | 6 | 7 |
| 16. Role of the funding body. | 6.5 | 6.5 | 6 | 6.5 |
aShould this item be included in the reporting checklist for updated clinical guidelines?;
bWhether this information was present or not would influence your perceptions of the completeness of the reporting of an updated clinical guideline;
cWhether this information was present or not would influence your perceptions of the usability of an updated clinical guideline;
dWhether this information was present or not would influence your perceptions of the quality of an updated clinical guideline.
* Seven-point Likert scale (0 meaning ¨strongly disagree¨ and 7 meaning ¨strongly agree¨).
Results of the external review with clinical guideline methodologists.
| Item | Median Score for Usability | Median Score for Confidence |
|---|---|---|
| 1. The updated version is distinguished from the previous version of the guideline. | 6 | 6 |
| 2. The sections reviewed in the updating process are described. | 7 | 6.5 |
| 3. The recommendations are clearly presented and labelled as new, modified, or no change. Deleted recommendations are clearly noted. | 6 | 6 |
| 4. The panel participants in the updated version are described. | 6 | 6 |
| 5. The rationale for updating the guideline is reported. | 6 | 6 |
| 6. Changes in the scope and purpose between the updated and original version are described and justified. | 6.5 | 6 |
| 7. Changes in the original recommendations are reported and justified. | 6 | 6 |
| 8. The methods used for searching and identifying new evidence in the updating process are described. | 7 | 7 |
| 9. The methods used for evidence selection in the updating process are described. | 7 | 7 |
| 10. The methods used to assess the quality of the included evidence in the updating process are described. | 7 | 7 |
| 11. The methods used for the evidence synthesis in the updating process are described. | 6 | 6 |
| 12. The methods and plan for implementing the changes of the updated version in practice are described. | 5 | 5 |
| 13. The methods used for externally reviewing the updated version are described. | 6 | 6 |
| 14. The plan and methods for updating the new version in the future are reported. | 6 | 6 |
| 15. The conflicts of interests of the group responsible for the updated version are recorded. | 7 | 7 |
| 16. The role of the funding body for the updated guideline is identified and described. | 7 | 7 |
aThis item is useful to evaluate an updated clinical guideline;
bI have more confidence in an updated clinical guideline if this item is reported.
* Seven-point scale (0 meaning ¨strongly disagree¨ and 7 meaning ¨strongly agree¨).
Final version of CheckUp.
| Item | Assessment | Reported on Page Number | Notes |
|---|---|---|---|
| 1. The updated version can be distinguished from the previous version of the clinical guideline. | Yes No Unclear Not applicable | ||
| 2. The rationale for updating the clinical guideline is reported. | Yes No Unclear Not applicable | ||
| 3. Changes in the scope and purpose between the updated and previous version are described and justified. | Yes No Unclear Not applicable | ||
| 4. The sections reviewed in the updating process are described. | Yes No Unclear Not applicable | ||
| 5. Recommendations are clearly presented and labelled as new, modified, or not changed. Deleted recommendations are clearly noted. | Yes No Unclear Not applicable | ||
| 6. Changes in recommendations are reported and justified. | Yes No Unclear Not applicable | ||
| 7. The panel participants in the updated version are described. | Yes No Unclear Not applicable | ||
| 8. Disclosures of interests of the group responsible for the updated version are recorded. | Yes No Unclear Not applicable | ||
| 9. The role of the funding body for the updated version is identified and described. | Yes No Unclear Not applicable | ||
| 10. The methods used for searching and identifying new evidence in the updating process are described. | Yes No Unclear Not applicable | ||
| 11. The methods used for evidence selection in the updating process are described. | Yes No Unclear Not applicable | ||
| 12. The methods used to assess the quality of the included evidence in the updating process are described. | Yes No Unclear Not applicable | ||
| 13. The methods used for the evidence synthesis in the updating process are described. | Yes No Unclear Not applicable | ||
| 14. The methods used for externally reviewing the updated version are described. | Yes No Unclear Not applicable | ||
| 15. The methods and plan for implementing the changes of the updated version in practice are described. | Yes No Unclear Not applicable | ||
| 16. The plan and methods for updating the new version in the future are reported. | Yes No Unclear Not applicable |